肝胆相照论坛

标题: Replicor将出席以色列协会肝大会在六月的研究和全球病毒性肝 [打印本页]

作者: StephenW 时间: 2015-6-11 14:31 标题: Replicor将出席以色列协会肝大会在六月的研究和全球病毒性肝

Replicor to Present at the Israel Association for the Study of Liver Conference and the Global Virus Hepatitis Summit in Berlin in JuneReplicor Inc.
Posted on: 10 Jun 15

More Replicor Inc. press releases

Replicor Inc. a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B (HBV) and hepatitis D (HDV) infection today announced that Dr. Andrew Vaillant Chief Scientific Officer will be presenting at two scientific conferences in June.
Dr. Vaillant has been invited to attend the Israel Association for the Study of Liver conference on June 11 where he will speak on “Application of Nucleic Acid Polymers for the Treatment of HBV and HDV Infection.”
Dr. Vaillant will also attend the Global Virus Hepatitis Summit in Berlin Germany June 26-28 where he will present on “REP 2139 Monotherapy and Combination Therapy with Pegylated Interferon: Safety and Potent Reduction of HBsAg and HDV RNA in Caucasian Patients with Chronic HBV / HDV Co-infection.” This important conference on the international calendar for the study of hepatitis and liver diseases occurs every three years. Dr. Vaillant will present updated clinical data subsequent to the data presented at EASL ILC conference in Vienna on April 24.
“These data continue to demonstrate the validity of our thesis for the treatment of hepatitis B and D and further validate the efficacy and safety of REP 2139 observed in the previous three Asian clinical trials” said Dr. Vaillant.
The data from the previous three clinical trials together with the preliminary data from the REP 301 trial demonstrate that REP 2139 used alone or in combination with Pegasys® or ZADAXIN® or Pegasys® and ETV is safe and well-tolerated. In these trials the antiviral response to REP 2139 when used as a backbone therapy in combination with various immunotherapies was profound with up to 7 log HBsAg reductions or clearance with accompanying = 6 log reductions or clearance of HBV DNA or HDV RNA. In HBV infected patients this combination approach appears to significantly increase the 12-month SVR rate achieved when compared to existing therapies.
About Replicor

More: http://www.pharmiweb.com/PressReleases/pressrel.asp?ROW_ID=117168#.VXkq30ZIVWU#ixzz3cjTtkFBz

作者: StephenW 时间: 2015-6-11 14:32

Replicor将出席以色列协会肝大会在六月的研究和全球病毒性肝炎峰会在柏林
Replicor公司
发表于：15年6月10日

更多Replicor公司新闻稿

Replicor公司靶向治疗患者的今天慢性乙型肝炎（HBV）和丁型肝炎（HDV）感染私人持有的生物制药公司宣布，安德鲁博士威能首席科学官将在两个科学会议在六月提出。

威能博士被邀请参加以色列协会为肝脏会议6月11日的研究，在那里他会说话的“核酸聚合物为HBV和HDV感染治疗中的应用。”

威能博士也将出席全球病毒性肝炎峰会在德国柏林6月26日至28日在那里他将提交一份关于“REP 2139单药和联合治疗与聚乙二醇干扰素：安全和白人患者强效减少HBsAg和HDV RNA的慢性HBV / HDV共感染。“在国际日历肝炎和肝脏疾病研究这个重要的会议发生每三年。威能博士将介绍更新为在维也纳国际劳工大会EASL会议4月24日提供的数据随后的临床数据。

“这些数据继续表明我们的观点的有效性进行乙肝和D的治疗和进一步验证REP 2139年的前三个亚洲临床试验中观察到的疗效和安全性”威能博士说。

从与来自REP 301试验的初步数据前三个临床试验的数据表明，REP 2139使用单独的或与Pegasys®或ZADAXIN®或Pegasys®和ETV组合是安全且耐受性良好。在这些试验中的各种免疫疗法组合治疗骨干一起使用时，REP 2139的抗病毒反应是深远的多达7日志HBsAg的减少或清除伴随= 6日志减少HBV DNA或RNA的HDV或清除。在HBV感染的患者该组合方法似乎显著增加时相比，现有疗法所取得的12个月的SVR率。

关于Replicor

更多：http://www.pharmiweb.com/PressRe ... 17168#.VXkq30ZIVWU#

作者: yelanglms 时间: 2015-6-11 14:43

These data continue to demonstrate the validity of our thesis for the treatment of hepatitis B and D and further validate the efficacy and safety of REP 2139 observed in the previous three Asian clinical trials” said Dr. Vaillant.

是指在亚洲做的三个临床试验，还是三个亚洲人的临床试验？

作者: StephenW 时间: 2015-6-11 14:54

回复 yelanglms 的帖子

在亚洲(孟加拉国)做的三个临床试验

作者: yelanglms 时间: 2015-6-11 15:01

StephenW 发表于 2015-6-11 14:54
回复 yelanglms 的帖子

在亚洲(孟加拉国)做的三个临床试验

这个药最大的问题，也许就是临床试验覆盖人群不多。
要是在多个国家做临床试验就好了。

作者: hao2014 时间: 2015-6-11 19:29

每年参加各种会议不少啊

欢迎光临肝胆相照论坛 (http://hbvhbv.info/forum/)